TRCT
JBIO

Tower Research Capital (TRC)’s Jade Biosciences JBIO Stock Holding History

Tower Research Capital (TRC)’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25K Sell
1,125
-3,827
-77% -$79.8K ﹤0.01% 3352
2026
Q1 		$69.6K Buy
4,952
+3,700
+296% +$53.6K ﹤0.01% 2469
2025
Q4 		$19.3K Sell
1,252
-653
-34% -$7.66K ﹤0.01% 3119
2025
Q3 		$16.4K Sell
1,905
-1,184
-38% -$9.68K ﹤0.01% 3475
2025
Q2 		$30.9K Buy
3,089
+2,965
+2,391% +$101K ﹤0.01% 3376
2025
Q1 		$10.9K Buy
124
+14
+13% +$1.23K ﹤0.01% 3604
2024
Q4 		$10.2K Sell
110
-29
-21% -$2.5K ﹤0.01% 3823
2024
Q3 		$10.2K Buy
139
+21
+18% +$1.35K ﹤0.01% 3790
2024
Q2 		$6.88K Buy
118
+59
+100% +$39.1K ﹤0.01% 4527
2024
Q1 		$60.9K Buy
59
+33
+127% +$25.2K ﹤0.01% 2142
2023
Q4 		$20.9K Sell
26
-15
-37% -$7.64K ﹤0.01% 3618
2023
Q3 		$19.5K Buy
41
+15
+58% +$8.12K ﹤0.01% 3401
2023
Q2 		$15.6K Sell
26
-51
-66% -$32.6K ﹤0.01% 3624
2023
Q1 		$55K Buy
77
+44
+133% +$36.5K ﹤0.01% 2396
2022
Q4 		$34K Sell
33
-66
-67% -$47.9K ﹤0.01% 2628
2022
Q3 		$57K Buy
99
+84
+560% +$56.1K ﹤0.01% 3033
2022
Q2 		$8K Sell
15
-26
-63% -$12.4K ﹤0.01% 4654
2022
Q1 		$26K Sell
41
-48
-54% -$18.6K ﹤0.01% 3276
2021
Q4 		$37K Buy
89
+77
+642% +$38.9K ﹤0.01% 3014
2021
Q3 		$9K Buy
12
+5
+71% +$2.8K ﹤0.01% 4407
2021
Q2 		$5K Buy
+7
New +$5.59K ﹤0.01% 4682

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tower Research Capital (TRC)'s JBIO Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Jade Biosciences (JBIO) stake by 77% in Q2 2026, selling an estimated $79.8K and leaving 1,125 shares worth $25K. The position accounts for ﹤0.01% of the portfolio, ranked #3352.

Tower Research Capital (TRC) first reported a position in JBIO in Q2 2021 and has held it in 21 quarters since. The position peaked at $69.6K in Q1 2026. 153 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Tower Research Capital (TRC) held 1,125 shares of Jade Biosciences worth $25K as of Q2 2026.
  • Tower Research Capital (TRC) sold 3,827 Jade Biosciences shares in Q2 2026, an estimated $79.8K.
  • Jade Biosciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3352 holding.
  • Tower Research Capital (TRC) first reported a position in Jade Biosciences in Q2 2021 and has held it in 21 quarters since.
  • Tower Research Capital (TRC)'s Jade Biosciences position peaked at $69.6K in Q1 2026.
  • 153 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.